Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Total revenues	$ 16,946	$ 9,984	$ 44,526	$ 28,301
Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,315	3,606	13,968	9,795
EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,274	3,415	15,075	8,581
APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,357	2,963	15,483	9,925
Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	8,405	6,948	18,291	19,134
Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	8,541	3,036	26,235	9,167
Performance Enzymes [Member]
Disaggregation of Revenue [Line Items]
Total revenues	12,125	9,984	34,019	28,301
Performance Enzymes [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,315	3,606	13,968	9,795
Performance Enzymes [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,453	3,415	4,568	8,581
Performance Enzymes [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,357	2,963	15,483	9,925
Performance Enzymes [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	8,405	6,948	18,291	19,134
Performance Enzymes [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	3,720	3,036	15,728	9,167
Novel Biotherapeutics [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,821	0	10,507	0
Novel Biotherapeutics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Total revenues	4,821	0	10,507	0
Novel Biotherapeutics [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0	0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 4,821	$ 0	$ 10,507	$ 0